Popular Articles

Genomas Presents Drug-Specific Genetic Determinants Of Statin Safety And Efficacy At The XV International Symposium On Atherosclerosis
Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, announced its participation at the prestigious XV International Symposium on Atherosclerosis, a meeting held triennially by the International Atherosclerosis Society. Gualberto Ruano, MD, PhD, President of Genomas, will present "Physiogenomic Contours of Statin Safety and Efficacy," a clinical study examining the differences in response to statin drugs based on individual gene variations.
buy viagra
ZIOPHARM Presents Positive Data From Phase I Study Of Palifosfamide In Combination With Doxorubicin At ASCO
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced that it presented final data from a Phase I study of palifosfamide (ZymafosTM) in combination with doxorubicin at the 45th Annual American Society of Clinical Oncology (ASCO) meeting held in Orlando, FL, May 29th to June 2nd.
News of the day
Anxiety's Hidden Cost
The effect of anxiety on academic performance is not always obvious but new research funded by the Economic and Social Research Council suggests that there may be hidden costs. The research found that anxious individuals find it harder to avoid distractions and take more time to turn their attention from one task to the next than their less anxious peers.
Cardiovascular

Altered Micriobiome Prevalent In The Diseased Esophagus: Findings Of NYU Langone Medical Center Researchers

Gastroesophageal reflux diseases , or GERD, affects about 10 million people in the United States, yet the cause and an unexpected increase in its prevalence over the last three decades remains unexplainable. Now, researchers have discovered that GERD is associated with global alteration of the microbiome in the esophagus. The findings, reported in the August 1, 2009 issue of Gastroenterology, may provide for the foundation for further study of the condition as a microecological disease with new treatment possibilities. The findings of an altered microbiome may have profound implications for treating diseases of the esophagus, among the most common disorders affecting Western populations. In fact, about 40% of adults experience heartburn symptoms at least once a month. Chronic inflammation associated with GERD can lead to the development of Barrett"s esophagus, precancerous condition. The incidence of cancer of the esophagus has increased six-fold since the 1970s--the fastest increasing cancer in the Western world. "These findings have opened a new approach to understanding the pathogenesis of reflux-related disorders," states Zhiheng Pei, MD, PhD, assistant professor of pathology and medicine at NYU Langone Medical Center and lead author of the study. "At this time, we don"t yet know whether the changes in bacterial populations are triggering GERD or are simply a response to it. But if changes in the bacterial population do indeed cause reflux, it may be possible to design new therapies with antibiotics, probiotic bacteria or prebiotics." Researchers collected and sequenced bacteria from the esophagus of 34 patients, both healthy and those suffering from GERD (specifically esophagitis and Barrett"s esophagus). They found a high concentration of Streptococcus in the esophagus of healthy patients. In contrast, an altered type of microbiome dominated by Gram-negative bacteria was contained in greater proportions in those patients with esophagitis and Barrett"s esophagus. The human microbiome is comprised of all the microorganisms that reside in or on the human body, as well as all their DNA, or genomes. Microbial cells in the human body are estimated to outnumber human cells by a factor of ten to one. These communities, or microbiomes, however remain largely unstudied, leaving almost entirely unknown their influence upon human development, physiology, immunity and nutrition. In order to analyze the makeup of these microbial organisms, the National Institutes of Health (NIH) launched the Human Microbiome Project in 2007 and awarded $115 million in research grants over five years to examine the relationship between the microbiome in a specific niche in the body to a particular disease. This study was sponsored by the NIH to examine how changes in microbioal populations correlate with changes in human health. Dorie Klissas NYU Langone Medical Center / New York University School of Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):